Celldex Therapeutics reported a net loss of $227.7 million for the first nine months of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet through stock issuances, ending the period with $650.3 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least twelve months.
Celldex Therapeutics reported third quarter 2026 financial results and provided a corporate update on its barzolvolimab program. The company highlighted positive Phase 3 topline results in chronic spontaneous urticaria (CSU) and anticipates a BLA submission in 2027.
“Barzolvolimab has significant potential to address enormous populations of high unmet need and shift the treatment paradigm goal from symptom improvement to complete symptom resolution, which for patients means no itch, no hives, no swelling.”
Anthony Marucci, Co-founder, President and Chief Executive Officer
“This quarter we reported best-in-disease results from our two Phase 3 studies in CSU, demonstrating barzolvolimab’s unparalleled ability to deliver complete response to patients—including even in patient populations suffering with severe disease or severe angioedema or with omalizumab refractory disease.”
Anthony Marucci, Co-founder, President and Chief Executive Officer